RCH-01 Development Status

RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia.  RepliCel’s proposed Phase 2 trial will enroll 160 male subjects in good health with mild to moderate androgenetic alopecia.  Dermal sheath cup cells will be isolated from a small punch biopsy taken from the back of the subject’s scalp.

These cells will be replicated and then reintroduced into balding areas on the subjects scalp.  After injections are performed subjects will return to the clinic for assessment of total, terminal and vellus hair density and cumulative hair thickness, as well safety.  Participants will remain in the trial for approximately 39 months.

Read More on Repicel